Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00145431 · ClinicalTrials.gov registry record · Phase 3
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT00145431 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 41 participants.
The verdict
NCT00145431, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug torcetrapib/atorvastatin in subjects with a rare genetically known disorder of high cholesterol and triglyceride levels.
Interventions
- DRUG atorvastatin
- DRUG fenofibrate
- DRUG torcetrapib/atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00145431
The ClinicalTrials.gov registry entry for NCT00145431 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which atorvastatin is the first listed.
NCT00145431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00145431 about?
NCT00145431 is a clinical study titled "Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Subjects With A Genetic Cholesterol Disorder.". The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug torcetrapib/atorvastatin in subjects with a rare genetically known disorder of high cholesterol and triglyceride levels.
What is the current status of trial NCT00145431?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2005-03. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00145431?
The interventions under investigation include: atorvastatin (DRUG), fenofibrate (DRUG), torcetrapib/atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00145431?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.